Gaps in Knowledge Persist Around Biosimilar Insulin Switching, Review Finds

Biosimilar-Backed Triplet Regimen Shows Feasibility in Heavily Pretreated Liver Cancer

February 27th 2026

By Skylar Jeremias

A phase 2 trial showed that combining targeted radiotherapy with PD-1 blockade and a bevacizumab biosimilar can elicit responses in advanced liver cancer.

Omalizumab Biosimilar Entry Linked to Expanded Patient Access, Reduced Spending

February 26th 2026

By Skylar Jeremias

Budget impact analysis finds omalizumab biosimilars in Europe could cut payer costs by €641M in 5 years, expanding access and driving major omalizumab savings.

Postmenopausal Osteoporosis: Clinical Burden, Treatment Barriers, and the Evolving Role of Denosumab Biosimilars

February 25th 2026

Cardinal Health Biosimilar Report: $56 Billion in Savings and the Road to Market Sustainability

February 24th 2026

By Skylar Jeremias

Biosimilars save billions, but FDA’s new guidance, physician concerns, and Humira switchbacks reveal hurdles to a sustainable US market.

Biosimilar Trastuzumab Emtansine Shows Consistent PFS in HER2-Positive Breast Cancer

February 20th 2026

By Skylar Jeremias

Real-world India data show trastuzumab emtansine biosimilars deliver meaningful PFS and manageable safety in heavily pretreated HER2+ metastatic breast cancer.

FDA Approves Filkri, Accord BioPharma’s Short-Acting Filgrastim Biosimilar for Neutropenia

February 18th 2026

By Sabrina McCrear

FDA approval of Filkri expands Accord’s G-CSF biosimilar portfolio, offering a short-acting option for neutropenia in cancer care.

Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 3rd 2026

By Skylar Jeremias

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 2nd 2026

By Sabrina McCrear

Mayo Clinic’s Chelsee Jensen, PharmD, discusses FDA policy changes, biosimilar development hurdles, denosumab lessons, and payer access strategies.

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28th 2026

By Skylar Jeremias

A new study confirms KM118, a proposed biosimilar to pertuzumab, shows pharmacokinetic similarity and safety, paving the way for affordable HER2-positive breast cancer treatments.

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27th 2026

By Skylar Jeremias

The US biosimilar market evolves with 90 approvals, significant price drops, and new PBM models enhancing access to cost-effective therapies.